Program
BBT002
A development code.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Nasal Polyps, led by Bambusa Therapeutics.
Furthest: phase 2, since Feb 22, 20263 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bambusa Therapeutics | 33 open or running | phase 2since Feb 22, 2026 | Apr 18, 2025 | Dec 31, 2026phase 1 · NCT07288554 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 18, 2025First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT06944925 · 286 planned · United States, Australia, Georgia and more
- Dec 16, 2025Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07288554 · 68 planned · China
- Feb 22, 2026Phase 2 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Phase 2 reachedNCT07436949 · 64 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07288554
- Jan 31, 2027Primary completion: phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06944925
- Dec 31, 2027Primary completion: phase 2 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07436949
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07436949Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · China | 2 | Recruiting | Dec 31, 2027 | 64 |
| NCT07288554Pulmonary Disease, Chronic Obstructive · China | 1 | Recruiting | Dec 31, 2026 | 68 |
| NCT06944925Pulmonary Disease, Chronic Obstructive · United States, Australia, Georgia and more | 1 | Recruiting | Jan 31, 2027 | 286 |
How it is read
Names in the registry
- “BBT002”, 3 entries
Codes read as this program: BBT002.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 2 studies
- Nasal Polyps, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.